LUNG CANCER MUTATION PANEL

Activating mutations in EGFR are present in approximately 10-12% of Non-Small cell carcinomas of the lung (Primarily Adenocarcinomas). EGFR mutation predict a good response to treatment with EGFR inhibitors like gefitinib and erlotinib. ALK rearrangement testing by FISH along with EGFR molecular testing are recommended for recurrent or metastatic cases with histological subtypes of Adenocarcinoma, Large cell carcinoma, or NSCLC NOS (not otherwise specified), and Squamous cell carcinoma in non-smokers or when biopsy specimens are small. FISH technique is the gold standard for detecting ALK-1 gene rearrangements.

  • Test Type:
  • Pre-test Information:
    No Special preparation required
  • Report Delivery:
    Sample by Tue 11 am; Report Mon
  • Components:
    0

Sample Report